First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
2Average reimbursement rates from commercial payers and Medicare - pricing pressure from payers directly impacts gross margins
3COVID-19 testing revenue trajectory - investors monitor the pace of decline and management's ability to replace pandemic revenue with core testing
4Operating expense burn rate and path to EBITDA breakeven - with negative margins, quarterly cash consumption and guidance on profitability timeline drive sentiment
5New product launches and test menu expansion - additions to oncology, pharmacogenomics, or rare disease panels signal competitive positioning
6Genetic testing services including hereditary cancer panels, carrier screening, and rare disease diagnostics (estimated 60-70% of current revenue)
7COVID-19 and respiratory pathogen testing services (estimated 20-30% of revenue, declining from pandemic peak)
8Biopharmaceutical services including clinical trial support and companion diagnostics (estimated 5-10% of revenue)
value/turnaround - The 0.6x price-to-book ratio and 38.5% one-year return attract deep value investors betting on operational turnaround…
Rising interest rates have minimal direct impact on Fulgent's operations given the 0.01 debt-to-equity ratio and negligible interest…
Watch on earnings: Monthly billable test volumes in core genetic testing categories (hereditary cancer, carrier screening, pediatric genetics) as leading indicator of revenue trajectory, Average reimbursement per test and payer mix (commercial vs Medicare/Medicaid) - commercial payers reimburse 2-3x government rates, Laboratory utilization rates and cost per test - breakeven typically requires 65-75% capacity utilization in molecular diagnostics.
One Sentence Summary:
Fulgent Genetics: the story is balanced — quarterly test volume trends in core genetic testing panels (hereditary cancer, reproductive health.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.